Core Viewpoint - NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, is set to provide a corporate update on December 2, 2025, focusing on recent clinical, regulatory, and operational developments [1]. Company Overview - NRx Pharmaceuticals specializes in Neuroplastic Therapies aimed at treating central nervous system disorders, including suicidal depression, PTSD, anxiety, and Autism [3]. - The company is developing two key products: NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone [3]. - NRX-100 has received Fast Track Designation for treating suicidal ideation in depression, while NRX-101 has been granted Breakthrough Therapy Designation for suicidal bipolar depression [3]. - An Abbreviated New Drug Application for NRX-100 has been filed, with a launch anticipated in July 2026 [3]. Subsidiary Information - HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is focused on creating a network of interventional psychiatry clinics that provide various therapies, including ketamine and transcranial magnetic stimulation [4]. - HOPE Therapeutics is the first network in Florida to offer the AMPA One Day (ONE-D) treatment, which combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine for treatment-resistant depression [4].

Core Insights - HOPE Therapeutics, Inc. has acquired a strategic interest in Cohen and Associates, LLC, integrating it into the HOPE Network, with Dr. Rebecca Cohen appointed as Medical Director overseeing care standards in Florida [1][9] Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focusing on building a network of interventional psychiatry clinics offering treatments such as ketamine and Transcranial Magnetic Stimulation (TMS) for patients with suicidal depression and related disorders [7] - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD, with products like NRX-100 and NRX-101 [6] Leadership and Expertise - Dr. Rebecca Cohen is a recognized expert in TMS and has a strong academic background, having founded her practice in 2014 as one of the first dedicated interventional psychiatry practices in the U.S. [3][9] - The leadership team at HOPE, including Dr. Cohen and Stephen Durand, RN, aims to advance interventional psychiatry and expand treatment options for patients [4][5] Strategic Goals - The acquisition of Cohen, LLC is expected to enhance HOPE Therapeutics' revenue and EBITDA, with immediate expansion plans in Western Florida and Palm Beach [9]